CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for hematologists, hematology-oncology fellows, medical oncologists and other healthcare providers involved in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.
  
  LEARNING OBJECTIVES

  • Develop an understanding of the scientific rationale for the development of CD19-directed chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells in patients with various forms of lymphoma.
  • Appreciate long-term efficacy and safety data with FDA-approved CAR T-cell therapies directed at CD19 in multiregimen-relapsed diffuse large B-cell lymphoma (DLBCL).
  • Identify patients with DLBCL and relapse on first-line therapy for whom treatment with CAR T-cell therapy would be appropriate.
  • Evaluate published research findings to determine the current clinical role of CAR T-cell therapy for patients with other B-cell lymphomas, including mantle cell lymphoma and follicular lymphoma.
  • Appreciate available data documenting the activity of CAR T-cell therapy in patients with relapsed/refractory chronic lymphocytic leukemia.
  • Implement strategies to educate patients eligible for treatment with CD19-directed CAR T-cell therapy about the potential for short- and long-term complications.

  

  ACCREDITATION STATEMENT
  CME credit is no longer available for this issue
  
  PHYSICIAN CONTINUING MEDICAL EDUCATION
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  DISCLOSURE & CONFLICT OF INTEREST POLICY
  Medical Learning Institute, Inc. (MLI) and Research To Practice (RTP) are committed to providing high-quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Joshua Brody, MD
  Director, Lymphoma Immunotherapy Program
  The Tisch Cancer Institute at Mount Sinai
  Faculty Member, Icahn Genomics Institute
  Icahn School of Medicine at Mount Sinai
  New York, New York
  
  No relevant conflicts of interest to disclose.
  
  Jason Westin, MD, MS
  Director, Lymphoma Clinical Research
  Section Chief, Aggressive Lymphoma
  Professor, Department of Lymphoma and Myeloma
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Consulting Agreements: AbbVie Inc, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Novartis, Nurix Therapeutics Inc, Pfizer Inc.
  
  MODERATOR
  Matthew Lunning, DO
  Associate Professor of Medicine
  Medical Director, Cellular Therapy
  Associate Vice Chair of Research
  Assistant Vice Chancellor for Clinical Research
  Division of Hematology/Oncology
  Department of Internal Medicine
  University of Nebraska Medical Center
  Omaha, Nebraska
  
  Consulting Honoraria: AbbVie Inc, Acrotech Biopharma, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Caribou Biosciences Inc, CRISPR Therapeutics, Daiichi Sankyo Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Nurix Therapeutics Inc, Recordati, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Vittoria Biotherapeutics; Research Funding: Bristol Myers Squibb, Fate Therapeutics, Sana Biotechnology.
  
  All of the relevant financial relationships of individuals for this activity have been mitigated.
  
  PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS — The planners and content/peer reviewers from Medical Learning Institute, Inc, the accredited provider, and Research To Practice, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
  
  SUPPORT STATEMENT
  This CE activity is supported through educational grants from Bristol Myers Squibb and Novartis.
  
  Release date: October 4, 2024
  Expiration date: October 5, 2025